ABX 1431

Drug Profile

ABX 1431

Alternative Names: ABX-1431

Latest Information Update: 28 Feb 2017

Price : $50

At a glance

  • Originator Abide Therapeutics
  • Developer Abide Therapeutics; University of Oxford
  • Class Analgesics; Anti-inflammatories; Small molecules
  • Mechanism of Action Cannabinoid receptor agonists; Monoacylglycerol lipase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Gilles de la Tourette's syndrome; Neurological disorders; Non-ulcer dyspepsia; Pain

Most Recent Events

  • 01 Feb 2017 Phase-I clinical trials in Gilles-de-la-Tourette's-syndrome in Germany (PO) (NCT03058562)
  • 01 Dec 2016 Phase-I clinical trials in Pain in United Kingdom (PO) (NCT02929264)
  • 01 Nov 2016 Phase-I clinical trials in Non-ulcer dyspepsia in Belgium (PO) (NCT02875678)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top